Skip to main content Skip to footer

Respiratory Syncytial Virus

Overview

Respiratory Syncytial Virus (RSV) is a common respiratory virus that can cause serious illness in infants and young children. In response to the expanded RSV prevention program launched by the Ministry of Health in fall 2024, BORN Ontario began collecting data to monitor uptake and outcomes of RSV immunization across the province. This initiative supports real-time surveillance and quality improvement efforts in perinatal and newborn care.

Why This Matters

RSV is a leading cause of hospitalization in infants. The expanded prevention program aims to reduce severe RSV outcomes through universal access to Beyfortus® (nirsevimab) for infants and Abrysvo™ for pregnant individuals. High-quality data collection is essential to evaluate program effectiveness, identify gaps in coverage, and inform future public health strategies.

BORN's Role

BORN Ontario integrated new RSV-related data elements into the BORN Information System (BIS) starting October 31, 2024. These include:

  • Administration and date of prenatal vaccine (Abrysvo™)
  • Administration and date of infant monoclonal antibody (Beyfortus®)
  • Reason for non-administration
  • High-risk criteria

BORN also developed RSV-specific reports to help hospitals and midwifery practice groups monitor uptake and outcomes locally and provincially.

Impact and Benefits of RSV Prevention and Surveillance

For Patients

  • Increased protection against severe RSV illness
  • Reduced hospitalizations and PICU admissions
  • Improved equity in access to care

For Providers

  • Real-time data to support clinical decision-making
  • Tools to monitor uptake and identify areas for improvement
  • Enhanced communication with families about RSV protection

 

For Healthcare

  • Reduced hospitalizations and PICU admissions
  • Fewer medically-attended RSV episodes
  • Efficient use of healthcare resources

Feature Story

Yemi’s story provides a glimpse into one family’s grim experience with RSV. The availability of new protective products and improved data collection/surveillance, however, represent marked progress toward the goal of ensuring all infants in Ontario receive the protection they need.

Stay Informed

This website uses cookies to enhance usability and provide you with a more personal experience. By using this website, you agree to our use of cookies as explained in our Website Privacy Policy.